• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by BioAge Labs Inc.

    4/17/25 4:10:03 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BIOA alert in real time by email
    DEFA14A 1 notice_and_access_card_-.htm DEFA14A DEFA14A

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the Securities

    Exchange Act of 1934 (Amendment No. )

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐

    Definitive Proxy Statement

    ☒

    Definitive Additional Materials

    ☐

    Soliciting Material Pursuant to §240.14a-12

     

    BIOAGE LABS, INC.

    (Name of Registrant as Specified In Its Charter)

    N/A

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒

    No fee required

    ☐

    Fee paid previously with preliminary materials

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     


     

    img152400874_0.jpg

    P.O. BOX 8016, CARY, NC 27512-9903 Your vote matters! BioAge Labs, Inc. Annual Meeting of Stockholders Thursday, June 5, 2025 3:30 PM, Eastern Time Annual meeting to be held virtually via the Internet - please visit www.proxydocs.com/BIOA for more details. You must register to attend the meeting online and/or participate at www.proxydocs.com/BIOA For a convenient way to view proxy materials, VOTE, and obtain directions to attend the meeting go to www.proxydocs.com/BIOA To vote your proxy while visiting this site, you will need the 12 digit control number in the box below. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting. Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the Internet. If you want to receive a paper or e-mail copy of the proxy material, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year's meeting, you must make this request on or before May 26, 2025. Meeting Materials: Notice of Meeting and Proxy Statement & Annual Report or Form 10-K Important Notice Regarding the Availability of Proxy Materials for the Stockholders Meeting to be Held on June 5, 2025 For Stockholders of Record as of April 10, 2025 To order paper materials, use one of the following methods.. Internet: www.investorelections.com/BIOA Call: 1-866-648-8133 Email: [email protected] * If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located below) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting material. Your control number Have the 12 digit control number located in the box above available when you access the website and follow the instructions. SEE REVERSE FOR FULL AGENDA Copyright © 2025 BetaNXT, Inc. or its affiliates. All Rights Reserved


     

    img152400874_1.jpg

    BioAge Labs, Inc. Annual Meeting of Stockholders THE BOARD OF DIRECTORS RECOMMENDS A VOTE: FOR ON PROPOSALS 1 AND 2 PROPOSAL 1. To elect three Class I directors, to serve a three-year term through the third annual meeting of stockholders following this meeting and until a successor has been elected and qualified or until earlier resignation or removal; 1.01 Kristen Fortney, Ph.D. 1.02 Eric Morgen, M.D. 1.03 Vijay Pande, Ph.D. 2. To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ended December 31, 2025. Note: To consider and vote upon such other business as may properly come before the meeting or any adjournment or postponement thereof.


    Get the next $BIOA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BIOA

    DatePrice TargetRatingAnalyst
    2/28/2025Mkt Perform
    William Blair
    12/10/2024$40.00 → $5.00Overweight → Underweight
    Morgan Stanley
    12/9/2024$42.00 → $7.00Buy → Hold
    Jefferies
    12/9/2024$45.00 → $7.00Buy → Neutral
    Citigroup
    10/21/2024$45.00Buy
    Citigroup
    10/21/2024$42.00Buy
    Jefferies
    10/21/2024$40.00Overweight
    Morgan Stanley
    More analyst ratings

    $BIOA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BioAge Labs to Present at Upcoming Investor Conferences

    EMERYVILLE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ:BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will participate in the following upcoming investor conferences: Citi's 2025 Biopharma Back to School Conference (Boston, September 2–3, 2025): Kristen Fortney, PhD, CEO and co-founder, and Dov Goldstein, MD, CFO, are scheduled to participate in a fireside chat on Wednesday, September 3 at 3:15–3:55 PM EDT, and will participate in one-on-one meetings. To access the live webcast of the presentation, regi

    8/20/25 4:30:00 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor

    First-in-human study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102, an orally available small molecule with potential best-in-class profile Initial development planned in obesity; BGE-102 demonstrated robust weight loss in preclinical models, both as monotherapy and in combination with GLP-1 receptor agonists Initial Phase 1 SAD data anticipated by end of 2025, with top-line readout of obesity study by end of 2026 EMERYVILLE, Calif., Aug. 15, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ:BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biolog

    8/15/25 9:00:00 AM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioAge Labs Reports Second Quarter 2025 Financial Results and Provides Business Updates

    Oral NLRP3 inhibitor BGE-102 on track for Phase 1 initiation in 2H 2025 with initial data by year-end Expanded APJ agonist pipeline through option agreement for novel antibody and advancement of proprietary oral small molecules Strengthened discovery platform through molecular profiling of 17,000+ samples from leading European HUNT Biobank EMERYVILLE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) --  BioAge Labs, Inc. ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today provided business updates and reported its second quarter 2025 financial results. "In

    8/6/25 4:30:00 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIOA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Pande Vijay Satyanand

    4 - BioAge Labs, Inc. (0001709941) (Issuer)

    8/11/25 4:14:24 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Hemrajani Rekha

    4 - BioAge Labs, Inc. (0001709941) (Issuer)

    6/9/25 4:47:25 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Healy James

    4 - BioAge Labs, Inc. (0001709941) (Issuer)

    6/9/25 4:46:16 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIOA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    William Blair initiated coverage on BioAge Labs

    William Blair initiated coverage of BioAge Labs with a rating of Mkt Perform

    2/28/25 7:20:24 AM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioAge Labs downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded BioAge Labs from Overweight to Underweight and set a new price target of $5.00 from $40.00 previously

    12/10/24 7:54:08 AM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioAge Labs downgraded by Jefferies with a new price target

    Jefferies downgraded BioAge Labs from Buy to Hold and set a new price target of $7.00 from $42.00 previously

    12/9/24 7:29:20 AM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIOA
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by BioAge Labs Inc.

    SCHEDULE 13G - BioAge Labs, Inc. (0001709941) (Subject)

    8/14/25 8:07:52 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by BioAge Labs Inc.

    SCHEDULE 13G/A - BioAge Labs, Inc. (0001709941) (Subject)

    8/14/25 3:01:06 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by BioAge Labs Inc.

    10-Q - BioAge Labs, Inc. (0001709941) (Filer)

    8/6/25 4:45:24 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIOA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Hemrajani Rekha bought $54,000 worth of shares (3,000 units at $18.00) (SEC Form 4)

    4/A - BioAge Labs, Inc. (0001709941) (Issuer)

    3/10/25 4:11:28 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Principal Accounting Officer Barton Shane bought $47,376 worth of shares (2,632 units at $18.00) (SEC Form 4)

    4 - BioAge Labs, Inc. (0001709941) (Issuer)

    3/10/25 4:10:37 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Pande Vijay Satyanand bought $4,329,019 worth of shares (219,195 units at $19.75) (SEC Form 4)

    4 - BioAge Labs, Inc. (0001709941) (Issuer)

    10/3/24 7:19:49 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIOA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by BioAge Labs Inc.

    SC 13G - BioAge Labs, Inc. (0001709941) (Subject)

    11/14/24 4:15:56 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by BioAge Labs Inc.

    SC 13G - BioAge Labs, Inc. (0001709941) (Subject)

    11/12/24 4:15:53 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by BioAge Labs Inc.

    SC 13D - BioAge Labs, Inc. (0001709941) (Subject)

    10/4/24 8:21:35 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care